Introduction
Pancreatic cancer (PC) is a lethal malignancy with an overall 5-year survival rate of only approximately 5% (1) . In 2008, PC was responsible for an estimated 268,800 deaths worldwide (2) . The poor prognosis of this disease is partly due to late clinical presentation and the lack of effective early detection measures. As a result, only 15-20% of patients with PC are candidates for potentially curative treatments at the time of diagnosis (3, 4) . Therefore, it is important to identify new and more effective biomarkers for early detection of PC.
MicroRNAs are endogenous single-stranded RNA molecules that are 18-24 nucleotides in length (5) . Mature microRNAs repress translation of mRNA into protein, and many microRNAs are highly conserved among species (6) . Many studies have demonstrated that microRNAs play roles in the regulation of crucial biological processes, including cellular proliferation, development, differentiation, metabolism, apoptosis, and immunity (7-13).
Tumors are equipped with multiple mechanisms to evade early events in immunological surveillance by regulating their susceptibility to lysis (14) . These mechanisms might involve modulation of microRNAs, which have significant impacts on the function of anti-tumor T cells (15) . Based on this idea, it would be useful to study the role of microRNAs in peripheral blood mononuclear cells PBMCs from cancer patients and normal subjects, and some of these expression changes appear to reflect specific immune responses of circulating cells (16, 17) . However, few studies have been performed on PBMC microRNAs, which could be of use as diagnostic biomarkers for PC.
Our study investigated PBMC microRNA expression profiles with independent validation in a large cohort of 352 participants, with the purpose of identifying microRNA markers for the diagnosis of PC. Healthy subjects, patients with PC, and patients with benign pancreatic/peripancreatic diseases (BPDs) were included in the cohort. The diagnostic performance of PBMC microRNA levels was assessed and compared with the widely used marker serum CA19-9.
Materials and Methods

Study Design and Patients
Blood samples from 352 patients who met the eligibility criteria (Supplementary Table S1 ) were collected at Zhongshan Hospital between January 2010 and January 2012. The samples were allocated to two sequential phases (Fig. 1 ). sequencing small RNAs from the three groups of samples. By comparing microRNA profiles between the PC and healthy groups, and between the PC and BPD groups, we established two differential microRNA expression patterns and subsequently compared them to each other. MicroRNAs that were significantly upregulated (fold change ≥2, normalized expression level of microRNA ≥100 in each sample) in both pairwise comparisons were chosen for further testing by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Subsequently, five of the microRNAs identified via sequencing were selected as candidates for further testing by qRT-PCR.
Validation phase. Five differentially expressed microRNAs identified
via sequencing were first tested by qRT-PCR in an independent cohort of PBMC samples from 100 participants. Three microRNAs that were differentially expressed between the PC group and both control groups (healthy subjects and BPD patients) were further tested in an additional 192 participants.
In each study phase, blood samples were obtained from three categories of participants: healthy subjects, patients with BPD, and patients with PC. The investigation protocol was approved by local institutional review boards, and informed consent was obtained from all study participants. No patient received chemotherapy or radiotherapy before blood sampling.
PBMC Preparation and RNA Isolation
For preparation of PBMCs, peripheral blood (5 ml) was drawn into EDTA Cancer Research. tubes and transferred to the laboratory within 30 min for blood processing.
PBMCs were isolated using lymphocyte separation medium (Sigma-Aldrich, USA), following the manufacturer's instructions.
For the PBMC samples, total RNA (covering all the small non-coding RNAs) was extracted using Trizol Reagent (Invitrogen, USA) according to the manufacturer's instructions. The concentration was quantified using a NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, Waltham, MA, USA). Each total RNA pellet was resuspended in 30 µl nuclease-free water and stored at -80°C. To validate the candidate microRNAs identified by sequencing, we performed qRT-PCR using Taqman microRNA assays (Applied Biosystems, Foster City, CA). The assays were first performed on 100 samples for five candidates (miR-27a-3p, miR-16-5p, miR-15b-5p, miR-26a-5p, and miR-342-3p) that met the aforementioned criteria for significant upregulation.
Sequencing and qRT-PCR
The expression level of RNU6B snRNA was used as a stable endogenous control for purposes of normalization. All assays were carried out in triplicate.
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Statistical Analysis
Differential expression of PBMC microRNAs, and differences in serum CA19-9 between PC and control groups (healthy and BPD) was analyzed 
Results
Patient Characteristics
The characteristics of the study participants in the validation phase are presented in Table 1 . Serum total bilirubin and CA19-9 of the study participants are also presented in Supplementary Table S3 . A total of 352 participants were recruited, including 149 patients with PC, 80 healthy subjects, and 123 patients with BPD. The BPD group used for sequencing (n=20) included patients with chronic pancreatitis (n=11), serous cystoadenoma (n=4), and pseudocyst (n=5). The BPD group used in the validation datasets (n=103) included patients with chronic pancreatitis (n=33), pseudocyst (n=15), autoimmune pancreatitis (n=4), serous cystoadenoma (n=15), benign cyst (n=2), lymphoepithelial cyst (n=1), and biliary calculus disease (n=33). The PC group used for sequencing (n=20) comprised 20 patients with pancreatic ductal adenocarcinoma (PDAC). The PC group used in the validation datasets (n=10), intraductal papillary mucinous carcinoma (n=6), solid pseudopapillary carcinoma (n=5), and acinar cell carcinoma (n=2).
MicroRNA Screening
First, HiSeq 2000 sequencing was performed to identify microRNAs that were significantly differentially expressed among the PC, healthy, and BPD groups. Supplementary Figure 1 illustrates the hierarchical clustering of the differentially expressed microRNAs in the three possible pairwise comparisons: PC vs. healthy, PC vs. BPD, and BPD vs. healthy. By comparing microRNA profiles between the PC and healthy groups and between the PC and BPD groups, we established two differential microRNA expression patterns that we then compared to each other. Five microRNAs, miR-27a-3p, miR-16-5p, miR-15b-5p, miR-26a-5p, and miR-342-3p, were significantly upregulated in the PC group relative to both the healthy and BPD groups (fold change ≥2, normalized expression level of microRNA ≥100 in each sample; Supplementary Table S4) . We selected these five differentially expressed microRNAs as candidates for further testing via qRT-PCR.
Independent Validation on PBMCs Samples
The five microRNAs identified via sequencing were first tested by qRT-PCR in an independent cohort of PBMC samples from 100 participants (Supplementary Table S5 ). Three of the five microRNAs were significantly upregulated in the PC group (n=40) relative to both the healthy group (n=30) and the BPD group (n=30). Those three microRNAs were further tested in an Tables S3). Significantly upregulated expression of miR-27a-3p, miR-16-5p, and miR-15b-5p was observed in patients with PC compared with subjects in both the healthy and BPD groups: average fold-change = 3.16, 2.30, and 2.40 for miR-27a-3p, miR-16-5p, and miR-15b-5p, respectively (Table 2 ; Fig. 2A-C) . Thus we analyzed these three microRNAs using a multivariate logistic regression model. In this model, as shown in Table 2 , only miR-27a-3p (P<0.001) effectively discriminated the PC group from the healthy and BPD groups. The corresponding AUCs were 0.857 (95% CI, 0.812-0.895; sensitivity = 82.2%; specificity = 79.1%).
The expression level of miR-27a-3p in PBMCs was comparable between strata by sex, age ({less than or equal to} 60 or > 60 years of age), levels of fasting blood glucose ({less than or equal to} or >17.1 umol) and CA19-9 ({less than or equal to} 37 or > 37 U/mL), or TNM stage. However, the level of miR-27a-3p expression in PC and BPD patients seem to be associated with elevated levels of total bilirubin (>17.1 umol/L) with the median (range) level of 85.48 (5.39-873.10) in patients with elevated serum total bilirubin versus 73.77 
Evaluating the diagnostic performance of serum CA19-9
Discrimination between PC patients and healthy subjects does not reflect the putative performance of the diagnostic test in a clinical setting. In this context, BPD patients represent a more suitable control. Therefore, we evaluated the diagnostic accuracy of serum CA19-9 in differentiating between the PC and BPD groups. For the purposes of this evaluation, we used the dataset from 232 patients from the validation phase (129 PC and 103 BPD) (Fig. 2D) . The resulting AUC was 0.788 (95% CI, 0.730-0.839; sensitivity = 72.9%; specificity = 75.7%).
Multiple linear regression analysis revealed that both PC (partial regression coefficient = 2.10; P<0.001) and jaundice (partial regression
0307 coefficient = 1.11; P<0.001) were predictors for serum CA19-9 in the validating dataset (PC, healthy, and BPD groups).
Establishing the Predictive Panel in a Clinical Setting
There were significant differences in the distributions of gender, total bilirubin, and fasting blood glucose between PC and BPD groups (Pearson χ2 test, p<0.05) in a clinical setting. Thus the five variables (including gender, total bilirubin, fasting blood glucose, miR-27a-3p and CA19-9) were analyzed in the validation phase by a multivariate logistic regression model. Only miR-27a-3p and CA19-9 were sufficiently effective in the model to discriminate PC from BPD group:
The diagnostic performance of the established panel was then evaluated using ROC analysis. The corresponding AUC was 0.886 (95% CI, 0.837-0.923; sensitivity= 85.3%; specificity=81.6%). The panel consisting of PBMC miR-27a-3p level and serum CA19-9 was significantly more effective than either individual marker alone at discriminating PC from BPD (vs. PBMC miR-27a-3p level: P=0.005; vs. serum CA19-9 level: P<0.001; Table 3 ). We 
Discussion
Lack of effective early detection measures is one of the most important factors contributing to the poor prognoses of PC patients. Serum CA19-9 has served for many years as a serum marker for PC diagnosis and screening.
However, the major limitation of CA19-9 as a diagnosis marker for pancreatic cancer is lack of specificity because it is also elevated in BPD (3, 4) . Extensive efforts to identify a better serum or plasma marker have met with limited success.
Immune system evasion in cancer patients is partially due to functional repression of immune cells (14, 15) For diagnosis of PC, the median sensitivity of serum CA19-9 is 79% (70-90%), and the median specificity is 82% (68-91%) (24), consistent with the diagnostic performance in our study. By contrast, a recent retrospective study showed that CA19-9 has poor clinical utility as a tumor marker for PC, with an AUC of only approximately 0.7 (25). This inconsistency might be related to case selection. Furthermore, elevation in serum CA19-9 is associated with hyperbilirubinemia irrespective of the presence of benign or malignant disease, compromising its diagnostic specificity (26). Our study also confirmed that hyperbilirubinemia is a predictor for elevation of serum CA19-9. Therefore, caution is warranted when interpreting the results in jaundiced patients. Marrelli et al. (27) demonstrated that serum CA19-9 decreases to normal levels when patients with benign pancreaticobiliary diseases are stented, but remains elevated in cases of malignancy. As with serum CA19-9, elevation of PBMC miR-27a-3p level was also related to hyperbilirubinemia in our study, potentially mitigating its diagnostic accuracy. However, owing to the complementary effect between the two biomarkers, the combination of serum stage I). In addition, whereas serum CA19-9 has been reported (24) to correlate with tumor stage, we did not observe such a correlation in this study.
This discrepancy could be attributed to the diversity of histological types of PC included in our cohorts.
Our study revealed that PBMC miR-27a-3p level was moderately accurate at differentiating PC from the control groups. In addition, its diagnostic performance was independent of disease staging; hence, it could serve as a potential diagnostic marker for PC at early stages. Previous reports those in the control groups, multivariate logistic regression analysis showed that these two microRNAs were not significant predictors for PC.
Our study has two unique advantages: First, we screened PBMC microRNAs using HiSeq 2000 sequencing technology, which enabled us to identify potential diagnostic markers with high accuracy. Moreover, our control group included not only healthy subjects, but also patients with BPD; as noted above, in a clinical setting, BPD patients represents a more suitable control group than healthy subjects. Our results indicate that our diagnostic panel could effectively differentiate PC from BPD.
Although our results are promising, there are several limitations in this study. First, we used pools of equal amounts of total RNA from 20 PC patients, 20 BPD patients, and 20 healthy subjects in the sequencing procedure, compromising the ability to identify differentially expressed microRNAs in PBMC. Moreover, PC group in this study included different types of pancreatic cancer. The potential marker miR-27a-3p we identified needs to be validated in a homogenous patient population with PDAC, which accounts for the vast majority of PC. In addition, the sample size is still small in present study, and we only performed internal validation of the algorithm using the open source package "pROC" for R and S-PLUS. Thus the panel identified in our study needs to be further validated using a large independent cohort. In summary, our study demonstrates that the combination of serum CA19-9 and PBMC miR-27a-3p level can differentiate PC from BPD with a Cancer Research. NOTE. ＊ Combination of PBMC miR-27a-3p and serum CA19-9. † logit(p=PC)＝-2.4597＋0.0239×miR-27a-3p＋0.0064×CA19-9.
Abbreviations: AUC, area under the receiver operating characteristic curve; PC, pancreatic cancer; BPD,benign pancreatic /peripancreatic diseases. 
